167 related articles for article (PubMed ID: 38833804)
1. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
[TBL] [Abstract][Full Text] [Related]
2. Nanovaccines with cell-derived components for cancer immunotherapy.
Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
[TBL] [Abstract][Full Text] [Related]
3. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted therapeutic applications of biomimetic nanovaccines.
Chheda D; Shete S; Tanisha T; Devrao Bahadure S; Sampathi S; Junnuthula V; Dyawanapelly S
Drug Discov Today; 2024 Jun; 29(6):103991. PubMed ID: 38663578
[TBL] [Abstract][Full Text] [Related]
5. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
[TBL] [Abstract][Full Text] [Related]
6. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
7. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
8. Nanobiomaterial-based vaccination immunotherapy of cancer.
Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
[TBL] [Abstract][Full Text] [Related]
9. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
10. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
11. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
12. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
[TBL] [Abstract][Full Text] [Related]
13. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy.
Meng L; Teng Z; Yang S; Wang N; Guan Y; Chen X; Liu Y
Nanoscale; 2023 Apr; 15(14):6432-6455. PubMed ID: 36916703
[TBL] [Abstract][Full Text] [Related]
14. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
[TBL] [Abstract][Full Text] [Related]
15. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
[No Abstract] [Full Text] [Related]
16. Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine.
Yang C; He Y; Chen F; Zhang F; Shao D; Wang Z
Small; 2023 Apr; 19(14):e2207029. PubMed ID: 36703529
[TBL] [Abstract][Full Text] [Related]
17. Nanovaccine: an emerging strategy.
Das A; Ali N
Expert Rev Vaccines; 2021 Oct; 20(10):1273-1290. PubMed ID: 34550859
[TBL] [Abstract][Full Text] [Related]
18. Nanovaccines for cancer immunotherapy.
Zhang Y; Lin S; Wang XY; Zhu G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
[TBL] [Abstract][Full Text] [Related]
19. A Versatile and Robust Platform for the Scalable Manufacture of Biomimetic Nanovaccines.
Hu H; Yang C; Zhang F; Li M; Tu Z; Mu L; Dawulieti J; Lao YH; Xiao Z; Yan H; Sun W; Shao D; Leong KW
Adv Sci (Weinh); 2021 Aug; 8(15):2002020. PubMed ID: 34386315
[TBL] [Abstract][Full Text] [Related]
20. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
